BridgeMD
New treatment option for Multiple Myeloma
Official title A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT05650632
What this study is testing
What is Etentamig (ABBV-383)?
Etentamig (ABBV-383) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for multiple myeloma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure.
- Phase 1: an early, usually small safety study
- Time commitment: about 3 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Must have measurable disease as outlined in the protocol.
- Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. Arm C and Arm D: ECOG performance of \<= 1.
- Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen...
- Must be naïve to treatment with etentamig (ABBV-383).
- Arm A: Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an...
You likely can't join if
- Arm A: Received BCMA-targeted therapy.
- Arm C and Arm D: Rapidly progressing disease per investigator.
See the full eligibility criteria
- Must have measurable disease as outlined in the protocol.
- Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. Arm C and Arm D: ECOG performance of \<= 1.
- Relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma...
- Must be naïve to treatment with etentamig (ABBV-383).
- Arm A: Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody.
- Arm B: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, an anti-CD38 monoclonal antibody, and a prior B-cell maturation antigen (BCMA)-targeted therapy (must be an anti-drug...
- Arm C: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig (ABBV-383).
- Arm D: Must have received at least 1 and no more than 3 prior lines of therapy, including exposure to a PI, an IMiD, or an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig...
- Arm A: Received BCMA-targeted therapy.
- Arm C and Arm D: Rapidly progressing disease per investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
- Springdale, Arkansas, United States
- Aurora, Colorado, United States
- Newark, Delaware, United States
- Hinsdale, Illinois, United States
- Fort Wayne, Indiana, United States
- Indianapolis, Indiana, United States
- New Orleans, Louisiana, United States
- Silver Spring, Maryland, United States
- Rochester, Minnesota, United States
- Lincoln, Nebraska, United States
- Omaha, Nebraska, United States
- New York, New York, United States
- Chapel Hill, North Carolina, United States
- Winston-Salem, North Carolina, United States
- Cincinnati, Ohio, United States
- Eugene, Oregon, United States
- Memphis, Tennessee, United States
- Nashville, Tennessee, United States
- Austin, Texas, United States
+ 25 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 3 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States; Springdale, Arkansas, United States; Aurora, Colorado, United States; Newark, Delaware, United States; Hinsdale, Illinois, United States; Fort Wayne, Indiana, United States and 39 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.